Pharming expands its equity position
Pharming Group NV has expanded its equity by negotiating the conversion of some of its convertible debt into shares and by issuing about one million new shares from a stand-by equity facility.
News
GW Pharmaceutics to research cannabinoids for metabolic disease
GW Pharmaceuticals Plc, which has a cannabinoid product for multiple sclerosis in registration in Europe, has entered an exclusive strategic alliance with a professor at the University of Buckingham to investigate cannabinoids for metabolic disease.
Boehringer to invest $42 million in potential Alzheimer’s treatment
Boehringer Ingelheim of Germany has announced plans to collaborate with the privately-held US firm, Vitae Pharmaceuticals Inc, to investigate beta-secretase inhibitors for the treatment of Alzheimer’s disease.
Allergy Therapeutics proposes a £22.4 million in share placement
Allergy Therapeutics Plc is proposing to raise up to £22.4 million in a private share placement which would give a group of South American investors up to 49.65% of the group’s enlarged share capital.
New technology for peptide drugs receives $40 million in funding
A US company with novel technology for making peptide drugs has received $40 million in a Series D funding from a syndicate that includes the venture capital arms of four major pharmaceutical companies.
Gloom lifts in London as Proximagen raises £50 million
A British medical discovery company with 25 employees, a history of losses and no products under clinical development is about to raise £50 million through a share sale on Britain’s junior stock market
Wellcome awards Novartis institute €5.15 million for vaccine project
The Wellcome Trust has awarded €5.15 million to a vaccine institute run by Novartis AG to investigate a new bivalent vaccine for Typhoid fever.
FDA asks Genmab for update of safety data for zalutumumab
The US Food and Drug Administration has asked Genmab A/S for an updated analysis of safety data for the monoclonal antibody, zalutumumab, which is being investigated for head and neck cancer.
AstraZeneca and Merck to collaborate on cancer treatment
In a second collaboration between two Big Pharma companies this year, AstraZeneca Plc and Merck & Co have announced plans to investigate the possible use of their respective, early-stage cancer treatments together, as a co-administered treatment.
GSK to collaborate with Concert Pharmaceuticals on deuterium-modified drugs
GlaxoSmithKline has announced a collaboration worth up to $1 billion with Concert Pharmaceuticals of Lexington, Mass, involving the use of deuterium chemistry to create novel small molecule drugs.